Think data
We help the life science industry to move from complex data to confident decisions, guided by clear, biology-driven insights.
A new narrative
In life sciences, the challenge isn’t generating data. It’s turning it into biological insights fast enough to guide real decisions.
BioLizard partners with organizations of all sizes—from small pharmaceutical companies and startups to leading biotech and pharma companies—to extract meaningful insights from complex biomedical data. Bio|Verse®, our modular analytics platform, enables intuitive exploration, custom workflows, and scalable infrastructure built around your science.
What sets us apart is how we pair this technology with expert collaboration and biology-driven thinking. Our teams work directly with yours to deliver clarity, speed, and better decisions.
Support across the drug development journey and beyond.
Drug development is complex. We help teams stay grounded in biology from discovery through clinical validation and beyond.
Discovery Research
Too much data, not enough direction. Our biology-first workflows and AI models help uncover real mechanisms and prioritize the targets worth pursuing so discovery starts focused.
Pre-Clinical & Translation
Data often sit in silos, disconnected from biology. We link molecular findings to physiological outcomes, building translational evidence that makes the next step clear.
Phase I → II → III
As studies scale, complexity grows. We connect clinical and molecular data across phases to reveal early signals, track response, and guide smarter trial design.
Post-Marketing Approval
The same analytical framework supports post-market work, including indication expansion, larger population analyses, and biological evidence generation for medical affairs teams.
And adjacent areas
The same biology-driven methods support work beyond human therapeutics. We apply insights from human biology to adjacent fields such as animal health, microbiome science, agriculture, and diagnostics, and transfer learnings back again when they strengthen human drug development.
Our unique combination of expert scientists with technology extend the limits of actionable insights.
Our biologists, data scientists, and engineers work alongside you to turn those outputs into decisions that move programs forward.
Our unique, proprietary, customizable Bio|Verse® gives teams the tools to explore and integrate data.
Introducing
Bio|Verse®
Bio|Verse® transforms insights into lasting value with interactive dashboards, scalable pipelines, and FAIR-compliant infrastructure, customized to your science.
Awards & rankings
These are the voices of our partners. With BioLizard, you don’t just get one expert, you tap into the collective strength of our team.
“Independent multi-omics and single-cell evidence confirmed therapeutic potential in a new indication — strengthening the client’s negotiation position and contributing to a $250M Novartis acquisition.”
“In-silico antibody mining identified new high-potency binders and accelerated discovery workflows, reducing manual analysis from days to minutes.”
“A fully automated, end-to-end analysis suite transformed complex metagenomics and metabolomics workflows into fast, standardized, and scalable processes.”
Meet the Lizards who make it happen >
Explore our case studies
Every project starts with a question and ends with insight that moves science forward. Our case studies show how biology-driven data science helps clients accelerate discovery, improve decision-making, and deliver real impact in pharma and biotech.
Beyond diagnostics: How biomarkers can be used to de-risk drug development
Biomarker discovery is important not only in the pursuit of better diagnostics but also for de-risking drug development. By leveraging validated biomarkers, you can prioritize drug candidates with higher likelihoods of therapeutic success, thereby reducing the risk of...
Microbial network analysis: How to unravel interactions between taxa
Studying the plant microbiome tells us which phyla, families or species (collectively referred to as ‘taxa’) are present in and around the plant, and how abundant they are. For example, the bacterial phyla Proteobacteria,...
Three ways you can extract information from plant microbiomes
In our last blog article, we detailed reasons why it is interesting to study plant microbiomes. Today, we will share an overview of the tools and techniques that scientists can leverage for this purpose. #1: Amplicon sequencing...
What have our Lizards been up to?
BioLizard Wins 2025 BioTech Breakthrough Award For “Bioinformatics Innovation of the Year”
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
Industry leader and multi-omics pioneer joins leadership team to advance AI-driven solutions
BioLizard has appointed Dr. Alexander Scheer as Chief Scientific Officer, adding 25+ years of translational R&D leadership across biotech and pharma. He will help scale BioLizard’s multi-omics and AI-driven strategy, strengthening work in biomarkers, precision medicine, and therapeutic innovation.
BioLizard Logs Stellar First Half of 2025: Growth, Innovation & Recognition
BioLizard’s first half of 2025 shows strong growth, AI innovation, and global recognition with new grants, leadership, and major industry awards.